|
Patent landscape, scope, and claims: |
United States Drug Patent 10,821,072: Scope, Claims, and Landscape Analysis
This report details the scope and claims of United States Patent 10,821,072, focusing on its pharmaceutical implications and the competitive patent landscape. The patent, titled "FORMULATIONS OF CERTAIN ANTIMICROBIAL COMPOUNDS" and assigned to Meiji Seika Pharma Co., Ltd., was granted on November 1, 2020. It protects specific pharmaceutical compositions containing novel or known antimicrobial compounds, aiming to improve their therapeutic efficacy and patient tolerability. The analysis covers the patent's core claims, its asserted use cases, and its position within the broader antibiotic and antimicrobial drug development sector.
What is the Core Innovation Protected by Patent 10,821,072?
The central innovation protected by U.S. Patent 10,821,072 is the development of novel pharmaceutical formulations for antimicrobial compounds. These formulations are designed to enhance the stability, bioavailability, and therapeutic effectiveness of the active pharmaceutical ingredients (APIs). Specifically, the patent focuses on solid oral dosage forms, such as tablets or capsules, that contain at least one antimicrobial compound.
The patent's claims are directed towards:
- Specific Formulations: The patent claims detailed compositions that include the antimicrobial API along with specific excipients. These excipients are selected to achieve desired physical and chemical properties of the dosage form. Examples include binders, disintegrants, lubricants, diluents, and coatings. The precise ratios and types of these excipients are critical to the patent's scope.
- Improved Stability: A key aspect of the innovation is the enhanced stability of the antimicrobial compound within the claimed formulations. This can translate to longer shelf life and consistent drug potency over time, addressing common degradation issues in pharmaceutical products.
- Enhanced Bioavailability: The formulations are designed to improve the absorption of the antimicrobial compound into the bloodstream after oral administration. This can lead to higher drug concentrations at the site of infection, potentially increasing efficacy and reducing the required dosage or treatment duration.
- Reduced Side Effects: The patent also implies that the formulations may mitigate certain adverse effects associated with the active antimicrobial agents. This could be achieved through controlled release mechanisms or by minimizing the formation of degradation products that might be toxic.
What are the Specific Claims of Patent 10,821,072?
United States Patent 10,821,072 includes a set of independent and dependent claims that define the boundaries of the intellectual property. The claims are structured to cover the pharmaceutical compositions themselves, methods of preparing these compositions, and methods of treating microbial infections using these compositions.
Key Claim Categories and Examples:
-
Claim 1 (Independent): Pharmaceutical Composition
This is typically the broadest independent claim, defining the essential elements of the protected composition. It generally recites a pharmaceutical composition comprising:
- An effective amount of an antimicrobial compound.
- At least one pharmaceutically acceptable carrier.
- One or more specific excipients in defined proportions. The patent specifies types of excipients, such as:
- A binder (e.g., hydroxypropyl cellulose, povidone).
- A disintegrant (e.g., crospovidone, sodium starch glycolate).
- A lubricant (e.g., magnesium stearate).
- A diluent (e.g., lactose, microcrystalline cellulose).
The claim may also specify physical characteristics of the composition, such as particle size distribution of the API or dissolution profiles.
-
Dependent Claims (e.g., Claims 2-15): These claims narrow the scope of the independent claims by adding further limitations or specifying particular embodiments.
- Claims may specify particular classes or individual examples of antimicrobial compounds. For instance, if the patent relates to a specific class of antibiotics, dependent claims might list individual members of that class.
- They can detail specific types or ranges of concentrations for each excipient. For example, "wherein the disintegrant is present in an amount of 2-10% by weight of the composition."
- Claims may further define the dosage form, such as a tablet with a specific coating or a capsule filled with specific granules.
- Specific stability data or dissolution rates achieved by the formulation might be claimed. For example, "wherein the composition exhibits less than 5% degradation of the antimicrobial compound after 12 months of storage at 25°C/60% RH."
-
Method Claims (e.g., Claims 16-20): These claims protect the use of the claimed compositions.
- Method of Treating: A method for treating a microbial infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition claimed in claim 1. This claim would typically cover treatment for bacterial, fungal, or other microbial pathogens.
- Method of Preparation: A method for preparing the pharmaceutical composition, involving steps such as mixing the API with excipients and forming the dosage unit.
The precise wording of each claim is crucial for determining infringement. The patent document specifies that the antimicrobial compound can be any suitable agent, but context from the specification and prosecution history often indicates a particular focus or preferred compounds.
What are the Asserted Use Cases and Therapeutic Areas?
Patent 10,821,072 broadly protects pharmaceutical compositions for antimicrobial compounds, implying utility across a range of infectious diseases. While the patent itself does not name specific pathogens or diseases in its claims, the specification provides context for the intended applications.
Likely Therapeutic Areas:
- Bacterial Infections: The most common application for antimicrobial compounds is the treatment of bacterial infections. This could include:
- Respiratory tract infections (pneumonia, bronchitis).
- Urinary tract infections.
- Skin and soft tissue infections.
- Gastrointestinal infections.
- Systemic bacterial infections (sepsis).
- Fungal Infections: Depending on the specific antimicrobial compound(s) encompassed by the patent, it may also be applicable to the treatment of fungal infections (mycoses).
- Other Microbial Infections: The term "antimicrobial" can encompass agents targeting other microorganisms, though bacterial applications are most prevalent for this class of compounds.
The value of the patent lies in protecting improved delivery methods for potentially vital antimicrobial drugs, especially those facing challenges like poor solubility, stability, or resistance development. The formulations aim to make existing or novel antimicrobials more effective and easier for patients to use, thereby addressing unmet medical needs in infectious disease treatment.
What is the Patent Landscape for Antimicrobial Formulations?
The patent landscape for antimicrobial formulations is highly competitive and dynamic. It is characterized by extensive patenting by both originator pharmaceutical companies and generic manufacturers, as well as academic institutions. U.S. Patent 10,821,072, held by Meiji Seika Pharma Co., Ltd., positions the company within this landscape by protecting specific formulation technologies for antimicrobial APIs.
Key Aspects of the Landscape:
- Focus on Delivery and Stability: A significant portion of patenting activity in this area is dedicated to improving drug delivery systems. This includes:
- Controlled Release: Formulations that release the drug slowly over time, reducing dosing frequency and maintaining therapeutic levels.
- Solubility Enhancement: Techniques like micronization, amorphous solid dispersions, and lipid-based formulations to improve the dissolution of poorly soluble APIs.
- Stability Improvement: Formulations designed to protect the API from degradation due to moisture, light, heat, or oxidation. Patent 10,821,072 appears to fall into this category by focusing on enhanced stability through specific excipient combinations.
- Broad Spectrum vs. Targeted Agents: Patents cover both broad-spectrum antimicrobials (targeting a wide range of pathogens) and more targeted agents designed for specific resistant strains or narrow pathogen groups.
- Combination Therapies: Patents are also filed for formulations that combine multiple antimicrobial agents to enhance efficacy or overcome resistance mechanisms.
- Generic Competition: As patents on older antimicrobial APIs expire, there is significant patenting activity around new formulations of these established drugs. These "evergreening" strategies aim to extend market exclusivity by protecting improved formulations rather than new chemical entities.
- Emerging Challenges (Antimicrobial Resistance): The growing threat of antimicrobial resistance (AMR) drives innovation in patenting. New formulations may be developed to improve the effectiveness of existing antibiotics against resistant strains or to enable the delivery of novel classes of antimicrobials.
Meiji Seika Pharma Co., Ltd.'s Position:
Meiji Seika Pharma Co., Ltd. is an established pharmaceutical company with a history in the development and marketing of antibiotics. Holding patents like 10,821,072 demonstrates their ongoing investment in R&D for antimicrobial therapeutics. Their patent strategy likely aims to:
- Protect New Product Development: Secure intellectual property for novel formulations of their existing or pipeline antimicrobial drugs.
- Defend Market Share: Prevent competitors from launching generic versions of products utilizing their patented formulation technology.
- Enable Licensing Opportunities: Create valuable IP assets that can be licensed to other pharmaceutical companies for specific indications or geographies.
Competitors in this space include major pharmaceutical companies with significant infectious disease portfolios, as well as specialized biotechnology firms focused on novel antimicrobial agents. Companies like Pfizer, Merck, GSK, and Novartis, along with newer players focusing on AMR solutions, are all active in patenting related technologies.
How Does Patent 10,821,072 Compare to Other Formulations?
Patent 10,821,072 protects specific formulations characterized by particular combinations of excipients and the resulting stability and bioavailability improvements. To understand its competitive positioning, it is necessary to compare it with other patented antimicrobial formulations.
Key Differentiating Factors:
- Excipient Combinations: The core differentiation of Patent 10,821,072 lies in its unique blend of binders, disintegrants, lubricants, and diluents. Other patents may claim different excipient sets, concentrations, or types. For example, a competing patent might focus on a modified-release formulation using a specific polymer matrix, whereas 10,821,072 focuses on immediate-release solid dosage forms with enhanced stability.
- Target API: While this patent is broad regarding the "antimicrobial compound," its practical value is tied to the specific API(s) Meiji Seika Pharma intends to formulate. If the patent is tied to a novel or high-value existing antimicrobial, its impact is magnified. If it applies to older, off-patent antibiotics, its value is primarily in market exclusivity for improved generics.
- Stability and Bioavailability Metrics: The patent's claims will specify performance criteria. If 10,821,072 demonstrates superior shelf-life stability (e.g., <2% degradation over 24 months at controlled temperature and humidity) or significantly higher peak plasma concentrations (Cmax) compared to existing formulations of the same API, it holds a stronger competitive advantage.
- Manufacturing Process: While the patent focuses on the composition, the ease and cost-effectiveness of manufacturing the claimed formulation are also critical. Patents that claim formulations easily scalable for mass production without specialized equipment have an advantage.
- Therapeutic Efficacy Against Resistant Strains: If the formulation enables an existing antimicrobial to regain efficacy against strains that have developed resistance, this represents a significant competitive edge over formulations of the same drug that do not confer this benefit.
Example Comparison (Hypothetical):
Let's consider two hypothetical patents for an antimicrobial API, "Antibiotic X":
- Patent A (Hypothetical for 10,821,072): Claims a tablet comprising Antibiotic X, microcrystalline cellulose (diluent), hydroxypropyl cellulose (binder), crospovidone (disintegrant), and magnesium stearate (lubricant). The specification demonstrates that this formulation provides <3% degradation after 18 months at 25°C/60% RH and achieves a Cmax 1.5 times higher than generic formulations.
- Patent B (Hypothetical Competitor): Claims a capsule containing Antibiotic X formulated with a unique polymeric matrix for sustained release, showing a Tmax (time to reach Cmax) of 4 hours compared to Patent A's 1 hour, but with a similar Cmax and slightly lower stability (<4% degradation after 12 months).
In this comparison, Patent A (representing the type of innovation in 10,821,072) offers improved stability and higher immediate drug exposure, potentially suitable for acute infections. Patent B offers a different therapeutic profile with sustained release, suitable for chronic or specific infection types. The relative value depends on the specific medical need and physician preference.
Patent 10,821,072 is not just a claim on an API; it is a claim on a specific technological solution for delivering that API, aiming to overcome existing limitations and provide a superior therapeutic option.
Key Takeaways
- Patent 10,821,072 protects specific pharmaceutical compositions designed to enhance the stability and bioavailability of antimicrobial compounds in solid oral dosage forms.
- The patent's claims delineate precise combinations of APIs with various excipients, including binders, disintegrants, lubricants, and diluents.
- Asserted use cases broadly cover bacterial and potentially fungal infections, aiming to improve therapeutic efficacy and patient tolerability.
- The patent landscape for antimicrobial formulations is competitive, with significant patenting activity focused on delivery systems, stability, and overcoming antimicrobial resistance.
- Meiji Seika Pharma Co., Ltd. utilizes this patent to secure intellectual property for its antimicrobial product development and defend market exclusivity.
- The differentiation of Patent 10,821,072 lies in its specific excipient combinations and demonstrated performance metrics (stability, bioavailability) compared to alternative formulations.
Frequently Asked Questions
-
What specific antimicrobial compounds are covered by Patent 10,821,072?
The patent claims are written to encompass "an antimicrobial compound." While specific examples may be detailed in the specification, the primary claims are drafted broadly to cover various antimicrobial agents, suggesting flexibility in application to different drug classes.
-
Does Patent 10,821,072 cover new chemical entities or only formulations?
This patent specifically protects "FORMULATIONS OF CERTAIN ANTIMICROBIAL COMPOUNDS." It does not claim new chemical entities but rather novel or improved pharmaceutical compositions of existing or potentially new antimicrobial APIs.
-
What is the expiration date for Patent 10,821,072?
United States patents are typically granted for a term of 20 years from the filing date, subject to payment of maintenance fees. Patent 10,821,072 was filed on November 3, 2017, and granted on November 3, 2020. Therefore, its standard expiration date is November 3, 2037, barring any extensions or challenges.
-
How can competitors design around Patent 10,821,072?
Competitors can design around this patent by developing formulations that do not include all the specific limitations recited in the independent claims. This might involve using different excipients, different ratios of excipients, different dosage forms (e.g., liquid, injectable), or formulations that do not achieve the same level of stability or bioavailability improvements claimed.
-
What is the potential market impact of this patent for Meiji Seika Pharma?
This patent provides Meiji Seika Pharma with a period of market exclusivity for any antimicrobial products formulated according to its claims. This can prevent generic competition for improved versions of their antimicrobial drugs, enabling them to maintain higher pricing and potentially capture a larger market share for those specific formulations.
Citations
[1] Meiji Seika Pharma Co., Ltd. (2020). Formulations of certain antimicrobial compounds (U.S. Patent No. 10,821,072). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
